Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Andrew Lane, Marlise Luskin, Julia Keating, Nicole Leboeuf, Jacqueline Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly-Puleo, Naval Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Anthony Selwyn Stein, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 653.

https://doi.org/10.1182/blood-2025-653

Published: 2025

Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Blood (2025) 146 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2025-3329

Published: 2025

Journal Articles

Prevalence and significance of cytoses in clonal hematpoiesis

Virginia Volpe, Keishla Arce-Ruiz, Yating Wang, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Alexander Bick, Marlise Luskin, R. Coleman Lindsley, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2025-1387

Published: 2025

Journal Articles

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Riya Nandi, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Marlise Luskin, R. Coleman Lindsley, Alexander Bick, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2025-1386

Published: 2025

Journal Articles

Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series

Erica Lamkin, Shai Shimony, Shefali Mehra, Andrew Lane, Justin Taylor

Blood (2025) 146 (Supplement 1): 6401.

https://doi.org/10.1182/blood-2025-6401

Published: 2025

Journal Articles

Unraveling KMT2A -rearranged ALL

Shai Shimony, Marlise R. Luskin

Blood (2023) 142 (21): 1764–1766.

https://doi.org/10.1182/blood.2023021942

Published: 2023

Journal Articles

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Miriam A. Osei, Lauren E. Merz, Kelly S. Chien, Danielle E. Hammond, Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Joan How, Mohammed Wazir, Anna E. Marneth, Shai Shimony, Ann Mullally, Daniel J. DeAngelo, Guillermo Garcia-Manero, Maureen Okam Achebe, Benjamin L. Ebert, Lachelle D. Weeks

Blood (2023) 142 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2023-172992

Published: 2023

Journal Articles

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley

Blood (2023) 142 (Supplement 1): 977.

https://doi.org/10.1182/blood-2023-173935

Published: 2023

Journal Articles

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Marlise R. Luskin, Shai Shimony, Julia Keating, Yael Flamand, Jacqueline S. Garcia, Rebecca Leonard, Thomas Reardon, Taylor Robertson, Chase M Weizer, Ilene Galinsky, Donna S. Neuberg, Richard M Stone, Eric S. Winer, Anthony G. Letai, Mark Alan Murakami, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2023-174216

Published: 2023

Journal Articles

Defining a Targetable Leukemia Intrinsic Dependency on Noncanonical PI3Kgamma Signaling

Qingyu Luo, Evangeline G. Raulston, Miguel A. Prado, Xiaowei Wu, Kira Gritsman, Kezhi Yan, Christopher A. G. Booth, Ran Xu, Peter van Galen, John G. Doench, Shai Shimony, Henry W. Long, Donna S. Neuberg, Joao A. Paulo, Andrew A. Lane

Blood (2023) 142 (Supplement 1): 578.

https://doi.org/10.1182/blood-2023-178895

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Organ Involvement in BPDCN Is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival

Shai Shimony, Julia Keating, Christopher Fay, Marlise R. Luskin, Donna S. Neuberg, Nicole R. Leboeuf, Andrew A. Lane

Blood (2023) 142 (Supplement 1): 2865.

https://doi.org/10.1182/blood-2023-172975

Published: 2023

Journal Articles

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Blood (2023) 142 (Supplement 1): 999.

https://doi.org/10.1182/blood-2023-187519

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Hari S. Raman, Shai Shimony, Yannis K. Valtis, Yael Flamand, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

Blood (2023) 142 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2023-178353

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Prevalence and significance of cytoses in clonal hematpoiesis

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series

Unraveling KMT2A -rearranged ALL

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults

Defining a Targetable Leukemia Intrinsic Dependency on Noncanonical PI3Kgamma Signaling

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Organ Involvement in BPDCN Is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only